Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Contrast Induced Nephropathy: full-pipeline trial registry
1 of 4 indexed Contrast Induced Nephropathy trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Contrast Induced Nephropathy: 4 US clinical trials tracked, 1 recruiting.
Contrast Induced Nephropathy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Hikari Dx, running 1 of these trials.
Enrollment posture brief
Registry condition contrast-induced-nephropathy
OPEN 1 | RECR 25% | LATE 1 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Contrast Induced Nephropathy lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Contrast Induced Nephropathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Contrast Induced Nephropathy is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
VA Office of Research and Development
NCT04982419
Clinical Validation of the RENISCHEM L-FABP POC Assay
Hikari Dx
NCT04864847
Contrast Nephropathy and Nitrates
Mt. Sinai Medical Center, Miami
NCT01999517
Remote Ischemic Preconditioning for Renal Protection in TAVI
Henry Ford Health System
NCT03347032
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Contrast Induced Nephropathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Contrast Induced Nephropathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Contrast Induced Nephropathy page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Contrast Induced Nephropathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Hikari Dx sponsors the most Contrast Induced Nephropathy trials on record, review their full trial history before evaluating a specific study. See Hikari Dx's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Contrast Induced Nephropathy condition card totals 4 registered trials; most-linked intervention IV Fluids; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.